Precision for Medicine Acquires ACT Oncology         

EnGeneIC chooses ACT Oncology as CRO for planned Phase I/IIa study in US

EnGeneIC has appointed ACT Oncology as a CRO for its planned Phase I/IIa study with end-stage oncology patients using its EDV based technology, said joint managing director Himanshu Brahmbhatt.The company is also open to partnering it’s EDV Platform, he added.

The Sydney, Australia based company has submitted an IND to the FDA for a truncated Phase I that will lead into a Phase IIa study to be conducted in the US with 40-50 patients toward YE2015 or early 2016, said Brahmbhatt.

Read Full Article

 

We're changing our name and website to reflect our exciting new capabilities since joining Precision for Medicine. Please visit us at precisionforoncology.com to see how we’re delivering the next generation of CRO services for oncology innovators.